Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;46(2):120-30.
doi: 10.1007/s12016-013-8378-7.

The hyper IgM syndromes

Affiliations
Review

The hyper IgM syndromes

Nashmia Qamar et al. Clin Rev Allergy Immunol. 2014 Apr.

Abstract

The hyper IgM syndromes are a group of rare inherited immune deficiency disorders characterized by impairment of immunoglobulin isotype switching resulting from defects in the CD40 ligand/CD40 signaling pathway. X-linked forms of hyper IgM are caused by defects in the CD40 ligand gene or NF-κB essential modulator, while autosomal recessive forms of hyper IgM are caused by defects in CD40 or downstream signaling molecules including activation-induced cytidine deaminase, uracil N glycosylase or postmeiotic segregation increased 2. The loss of interaction between CD40 and its ligand results in an impairment of T cell function, of B cell differentiation and of monocyte function while only B cell differentiation appears to be affected in defects of sinaling molecules downstream of CD40 with the exception of defects of the NF-κB complex, which mediates signaling via multiple receptor pathways. With many genetic defects in the hyper IgM syndrome identified, it is possible to diagnose patients definitively, to perform genetic screening, and to delineate the clinical manifestations of the different diseases in this syndrome. Stem cell transplantation is an available therapeutic option for defects that result in a combined immunodeficiency while antibody replacement appears sufficient for the strictly humoral immunodeficiencies.

PubMed Disclaimer

References

    1. J Pediatr. 1997 Jul;131(1 Pt 1):47-54 - PubMed
    1. J Allergy Clin Immunol. 2012 Dec;130(6):1414-6 - PubMed
    1. Nat Immunol. 2001 Mar;2(3):223-8 - PubMed
    1. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2110-4 - PubMed
    1. J Clin Invest. 2008 Sep;118(9):3132-42 - PubMed

MeSH terms

LinkOut - more resources